How abhorrent to find it necessary to speak about defensive measures, such as going to the Expert Market to avoid the regulatory minefield of being on a trading venue, when one hour earlier, I questioned the possibility of lenz proving to be a cure for covid and certain cancers.
But, that is our reality. It's a reality made even worse by shareholders who fault management for the strategic positioning of the company on the Expert Market, and they don't even try to understand why management would this, not even when reason is before them.
In my opinion, the only material weakness or reportable event relevant to us has been our negligently-delayed authorization from the FDA and NIH/NIAID, which by now could have caused millions of preventable deaths worldwide, since our EUA application was submitted.
Nevertheless, I think management's strategic positioning of the company will prove successful, and will enable the use of lenzilumab to help stamp out covid and certain cancers. You would think health regulators would want that.
News 
Market Data 
Discover 
